Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 91

1.

Combining intratumoral Treg depletion with androgen deprivation therapy (ADT): preclinical activity in the Myc-CaP model.

Shen YC, Ghasemzadeh A, Kochel CM, Nirschl TR, Francica BJ, Lopez-Bujanda ZA, Carrera Haro MA, Tam A, Anders RA, Selby MJ, Korman AJ, Drake CG.

Prostate Cancer Prostatic Dis. 2018 Apr;21(1):113-125. doi: 10.1038/s41391-017-0013-x. Epub 2017 Dec 4.

2.

Combining immune check-point blockade and cryoablation in an immunocompetent hormone sensitive murine model of prostate cancer.

Benzon B, Glavaris SA, Simons BW, Hughes RM, Ghabili K, Mullane P, Miller R, Nugent K, Shinder B, Tosoian J, Fuchs EJ, Tran PT, Hurley PJ, Vuica-Ross M, Schaeffer EM, Drake CG, Ross AE.

Prostate Cancer Prostatic Dis. 2018 Apr;21(1):126-136. doi: 10.1038/s41391-018-0035-z. Epub 2018 Mar 20.

3.

Effective combinatorial immunotherapy for castration-resistant prostate cancer.

Lu X, Horner JW, Paul E, Shang X, Troncoso P, Deng P, Jiang S, Chang Q, Spring DJ, Sharma P, Zebala JA, Maeda DY, Wang YA, DePinho RA.

Nature. 2017 Mar 30;543(7647):728-732. doi: 10.1038/nature21676. Epub 2017 Mar 20. Erratum in: Nature. 2017 May 3;545(7652):116.

4.

Poxvirus-based active immunotherapy synergizes with CTLA-4 blockade to increase survival in a murine tumor model by improving the magnitude and quality of cytotoxic T cells.

Foy SP, Mandl SJ, dela Cruz T, Cote JJ, Gordon EJ, Trent E, Delcayre A, Breitmeyer J, Franzusoff A, Rountree RB.

Cancer Immunol Immunother. 2016 May;65(5):537-49. doi: 10.1007/s00262-016-1816-7. Epub 2016 Mar 10.

5.

Increased CD8+ T-cell function following castration and immunization is countered by parallel expansion of regulatory T cells.

Tang S, Moore ML, Grayson JM, Dubey P.

Cancer Res. 2012 Apr 15;72(8):1975-85. doi: 10.1158/0008-5472.CAN-11-2499. Epub 2012 Feb 28.

6.

Androgen deprivation induces phenotypic plasticity and promotes resistance to molecular targeted therapy in a PTEN-deficient mouse model of prostate cancer.

De Velasco MA, Tanaka M, Yamamoto Y, Hatanaka Y, Koike H, Nishio K, Yoshikawa K, Uemura H.

Carcinogenesis. 2014 Sep;35(9):2142-53. doi: 10.1093/carcin/bgu143. Epub 2014 Jul 1.

7.

NDRG2 acts as a negative regulator downstream of androgen receptor and inhibits the growth of androgen-dependent and castration-resistant prostate cancer.

Yu C, Wu G, Li R, Gao L, Yang F, Zhao Y, Zhang J, Zhang R, Zhang J, Yao L, Yuan J, Li X.

Cancer Biol Ther. 2015;16(2):287-96. doi: 10.1080/15384047.2014.1002348.

8.

Paracrine sonic hedgehog signaling contributes significantly to acquired steroidogenesis in the prostate tumor microenvironment.

Lubik AA, Nouri M, Truong S, Ghaffari M, Adomat HH, Corey E, Cox ME, Li N, Guns ES, Yenki P, Pham S, Buttyan R.

Int J Cancer. 2017 Jan 15;140(2):358-369. doi: 10.1002/ijc.30450. Epub 2016 Oct 20.

9.

In situ vaccination combined with androgen ablation and regulatory T-cell depletion reduces castration-resistant tumor burden in prostate-specific pten knockout mice.

Akins EJ, Moore ML, Tang S, Willingham MC, Tooze JA, Dubey P.

Cancer Res. 2010 May 1;70(9):3473-82. doi: 10.1158/0008-5472.CAN-09-2490. Epub 2010 Apr 20.

10.

Castration induces autoantibody and T cell responses that correlate with inferior outcomes in an androgen-dependent murine tumor model.

Hahn S, Nesslinger NJ, Drapala RJ, Bowden M, Rennie PS, Pai HH, Ludgate C, Nelson BH.

Int J Cancer. 2009 Dec 15;125(12):2871-8. doi: 10.1002/ijc.24673.

11.

Combined immunotherapy: CTLA-4 blockade potentiates anti-tumor response induced by transcutaneous immunization.

Rausch J, Lopez PA, Bialojan A, Denny M, Langguth P, Probst HC, Schild H, Radsak MP.

J Dermatol Sci. 2017 Sep;87(3):300-306. doi: 10.1016/j.jdermsci.2017.06.013. Epub 2017 Jun 16.

PMID:
28666747
12.

Vascular responses to radiotherapy and androgen-deprivation therapy in experimental prostate cancer.

Røe K, Mikalsen LT, van der Kogel AJ, Bussink J, Lyng H, Ree AH, Marignol L, Olsen DR.

Radiat Oncol. 2012 May 23;7:75. doi: 10.1186/1748-717X-7-75.

13.

TCF7 is suppressed by the androgen receptor via microRNA-1-mediated downregulation and is involved in the development of resistance to androgen deprivation in prostate cancer.

Siu MK, Chen WY, Tsai HY, Chen HY, Yin JJ, Chen CL, Tsai YC, Liu YN.

Prostate Cancer Prostatic Dis. 2017 Jun;20(2):172-178. doi: 10.1038/pcan.2017.2. Epub 2017 Feb 21.

PMID:
28220803
14.

Numb-/low Enriches a Castration-Resistant Prostate Cancer Cell Subpopulation Associated with Enhanced Notch and Hedgehog Signaling.

Guo Y, Zhang K, Cheng C, Ji Z, Wang X, Wang M, Chu M, Tang DG, Zhu HH, Gao WQ.

Clin Cancer Res. 2017 Nov 1;23(21):6744-6756. doi: 10.1158/1078-0432.CCR-17-0913. Epub 2017 Jul 27.

15.

Prostate cancer bone metastases acquire resistance to androgen deprivation via WNT5A-mediated BMP-6 induction.

Lee GT, Kang DI, Ha YS, Jung YS, Chung J, Min K, Kim TH, Moon KH, Chung JM, Lee DH, Kim WJ, Kim IY.

Br J Cancer. 2014 Mar 18;110(6):1634-44. doi: 10.1038/bjc.2014.23. Epub 2014 Feb 11.

16.

Enhancing the effectiveness of androgen deprivation in prostate cancer by inducing Filamin A nuclear localization.

Mooso BA, Vinall RL, Tepper CG, Savoy RM, Cheung JP, Singh S, Siddiqui S, Wang Y, Bedolla RG, Martinez A, Mudryj M, Kung HJ, Devere White RW, Ghosh PM.

Endocr Relat Cancer. 2012 Nov 9;19(6):759-77. doi: 10.1530/ERC-12-0171. Print 2012 Dec.

17.

Methylselenocysteine preventing castration-resistant progression of prostate cancer.

Liu Y, Liu X, Guo Y, Liang Z, Tian Y, Lu L, Zhao X, Sun Y, Zhao X, Zhang H, Dong Y.

Prostate. 2015 Jun 15;75(9):1001-8. doi: 10.1002/pros.22987. Epub 2015 Mar 8.

18.

Patient-derived tissue slice grafts accurately depict response of high-risk primary prostate cancer to androgen deprivation therapy.

Zhao H, Thong A, Nolley R, Reese SW, Santos J, Ingels A, Peehl DM.

J Transl Med. 2013 Aug 28;11:199. doi: 10.1186/1479-5876-11-199.

19.

Checkpoint Kinase 2 Negatively Regulates Androgen Sensitivity and Prostate Cancer Cell Growth.

Ta HQ, Ivey ML, Frierson HF Jr, Conaway MR, Dziegielewski J, Larner JM, Gioeli D.

Cancer Res. 2015 Dec 1;75(23):5093-105. doi: 10.1158/0008-5472.CAN-15-0224. Epub 2015 Nov 16.

20.

Combination of tumor site-located CTL-associated antigen-4 blockade and systemic regulatory T-cell depletion induces tumor-destructive immune responses.

Tuve S, Chen BM, Liu Y, Cheng TL, Touré P, Sow PS, Feng Q, Kiviat N, Strauss R, Ni S, Li ZY, Roffler SR, Lieber A.

Cancer Res. 2007 Jun 15;67(12):5929-39.

Supplemental Content

Support Center